These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26911627)

  • 41. International Conference on Harmonisation; Guidance on E2F Development Safety Update Report; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(163):52667-8. PubMed ID: 21894658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of research: is it a drug trial or a supplement trial?
    Chen ST
    Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA drug classification system.
    Sanborn MD; Godwin HN; Pessetto JD
    Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDA review practices and priorities for drugs used in cancer treatment.
    Kobayashi K; DeLap RJ
    Ann N Y Acad Sci; 2001 Dec; 949():341-4. PubMed ID: 11795373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective.
    Wu C; Lee SL; Taylor C; Li J; Chan YM; Agarwal R; Temple R; Throckmorton D; Tyner K
    J Nat Prod; 2020 Feb; 83(2):552-562. PubMed ID: 31977211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs.
    Ross JS; Dzara K; Downing NS
    Health Aff (Millwood); 2015 Apr; 34(4):681-8. PubMed ID: 25847652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigational new drug applications and new drug applications--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(28):6854-62. PubMed ID: 10177736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 54. Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in Taiwan.
    Sun IC
    Invest New Drugs; 2019 Oct; 37(5):1094-1106. PubMed ID: 30612310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory issues of importance to developing anti-HIV therapeutics.
    Hastings KL
    Toxicol Pathol; 1996; 24(3):278-80. PubMed ID: 8736383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The "Drug export lag" and the Drug Export Amendments Act of 1986: an evaluation.
    Pathak DS; Hakim Z; Kucukarslan S
    Clin Ther; 1994; 16(2):283-305; discussion 271-2. PubMed ID: 8062323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. U.S. Regulatory Considerations for Development of Live Biotherapeutic Products as Drugs.
    Dreher-Lesnick SM; Stibitz S; Carlson PE
    Microbiol Spectr; 2017 Oct; 5(5):. PubMed ID: 28975881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.